I work in IT security, which means I spend a lot of time thinking about systems that can be compromised. When I first read about Neuralink’s human trials in early 2024, my first reaction was not excitement. It was a specific kind of professional concern: you are proposing to put a wireless-connected computer inside a human skull, and I want to know exactly what the attack surface looks like.
That concern has not gone away. But the more I read into what the first trials actually produced — the real data, not the Elon Musk press conferences — the more I think this technology deserves a more careful look than most coverage gives it.
Here is what actually happened, what it means, and where the gaps are.
The Basic Setup: What the Device Is
The Neuralink implant, called the Link, is a coin-sized device that sits flush with the skull after a small section of bone is removed. From that disc, 1,024 electrodes on ultra-thin flexible threads are inserted into brain tissue — specifically into the motor cortex, the region that controls voluntary movement.
The threads are thinner than a human hair, which creates a mechanical problem: the human hand cannot place them without causing damage to surrounding tissue and blood vessels. Neuralink’s solution was to build a surgical robot, the R1, that handles the insertion with precision the unaided hand cannot match. The robot identifies blood vessels in real time and routes the threads around them.
The device reads electrical activity from neurons — specifically the firing patterns that correspond to intended movement — and transmits that data wirelessly to an external receiver. The processing then translates those patterns into computer commands.
What the First Patient Actually Did
Noland Arbaugh, a 29-year-old who became paralyzed from the shoulders down after a diving accident, received the first implant in January 2024. The results that got reported — playing chess, controlling a cursor, navigating a laptop — were real. What the coverage usually omitted was the more nuanced version of events.
Arbaugh confirmed in subsequent interviews that the system worked by having him imagine moving his hand. The device detected the neural firing pattern associated with that imagined movement and used it as input. This is not reading thoughts in any meaningful sense — it is reading motor intention signals, which is a narrower and more specific thing.
In the weeks following implantation, Neuralink disclosed that some of the electrode threads had retracted from the brain tissue, reducing the number of working electrodes. The company adjusted its software to compensate, and Arbaugh reported continued functionality. But the retraction issue is worth noting: the brain is not a static substrate. It moves slightly with every heartbeat and every head movement, and keeping thin threads anchored in soft tissue over months and years is an unsolved engineering problem.
A second patient received an implant in 2024 as well. The FDA’s expanded approval for the PRIME study allowed Neuralink to implant devices in additional participants, with the trial focused on establishing safety and feasibility rather than long-term outcomes.
The Engineering Problems That Do Not Get Enough Coverage
Most articles about Neuralink focus on what the technology promises. The engineering constraints that exist right now get less attention.
Signal degradation over time. Electrodes implanted in brain tissue trigger a response from the immune system. Glial cells form a scar around the electrodes, progressively insulating them and reducing signal quality. This is a known problem across all neural interface research, not specific to Neuralink. How the Link performs over five or ten years, nobody knows yet, because no device like it has been in humans long enough to find out.
Wireless transmission. The device communicates via Bluetooth. In a security context, this is a flag. The current generation is designed for medical use in controlled settings, and the data being transmitted — motor intention signals from a paralyzed patient — is not the kind of data a sophisticated attacker has obvious reasons to intercept. But the question of what a more capable future version transmits, and how that channel is secured, matters. The research community has published proof-of-concept work on BCI vulnerabilities, and it is not a theoretical concern.
Battery and longevity. The Link is powered by a small battery that recharges wirelessly through the skull. What happens to the device if the battery degrades, or if the company that manufactured it ceases to support the hardware or software? Medical device obsolescence is a real issue, and brain-implanted devices present a specific version of it.
The Competitors Doing This Differently
Neuralink is the most prominent name in brain-computer interfaces, but it is not the only serious effort.
Synchron, a company that received FDA breakthrough device designation before Neuralink, takes a different approach entirely: their device is delivered through the jugular vein and lodges in a blood vessel adjacent to the motor cortex, reading neural activity without direct penetration of brain tissue. The tradeoff is lower signal resolution compared to electrodes in direct contact with neurons, but the procedure is dramatically less invasive. Synchron has implanted devices in multiple patients, including in the United States.
Blackrock Neurotech has been working in this space for longer than either Neuralink or Synchron and has maintained implants in patients for years. Their work has contributed a significant portion of the foundational research on what chronic neural interfaces actually look like in humans over time.
The competitive field here is not winner-take-all. Different approaches will likely prove suited to different applications.
What Musk Actually Says, And Why It Matters to Be Precise
Elon Musk has described a long-term vision where healthy humans augment their cognitive capabilities with neural implants — increasing what he calls “bandwidth” between human thought and digital systems, in part as a response to the perceived risk that artificial intelligence will outpace unaugmented human capability.
This is worth being precise about, because the gap between current reality and that vision is enormous. The first-generation device reads motor intention signals from one region of the brain for the specific purpose of enabling paralyzed patients to control computers. Translating that into general cognitive augmentation for healthy people involves problems that are not close to being solved: mapping and interpreting the neural correlates of complex thought, managing the tissue response to long-term implants, understanding the neurological effects of chronic electrical activity from implanted electrodes, and building the software infrastructure to make any of it useful.
The near-term medical applications — restoring communication and mobility for people with paralysis or ALS — are meaningful and achievable with current technology. The transhumanist applications are a different category of problem entirely.
The Questions Worth Taking Seriously
Whether or not you find the long-term vision credible, some of the ethical questions raised by this technology are worth engaging with seriously rather than dismissing.
Data generated by a brain-computer interface belongs in a different category than data generated by a smartphone. The question of who owns it, who can access it, and under what circumstances is not answered by current legal frameworks. The consumer privacy laws that govern app data were not written with neural data in mind.
The question of equitable access matters too, but it is worth framing carefully. The immediate beneficiaries of the current trials are people with severe paralysis who currently have limited options. The concern about a two-tier society of “enhanced” and “unenhanced” humans is a legitimate long-term question, but framing it as an immediate objection to medical trials for paralyzed patients conflates two different timeframes.
And the security question, which I keep coming back to: a device that reads neural signals and communicates wirelessly exists in a threat landscape. That risk needs to be taken seriously by the researchers and companies building these systems, and the security community needs to be involved in that conversation earlier rather than later.
Where This Actually Stands
Neuralink’s first human trial demonstrated that a high-density neural interface can be implanted safely enough to proceed to a small multi-patient study. It demonstrated that a paralyzed patient can use the device to control a computer with meaningful accuracy. It also revealed an engineering challenge with electrode retention that the company is working around rather than having solved.
That is a meaningful result. It is not proof of concept for cognitive augmentation in healthy people. It is not the beginning of a “cyborg era.” It is an early-stage medical device trial that produced encouraging safety data and demonstrated functional use in a patient who had no other good options.
The technology will probably improve. The electrode retention problem may be solved. Signal resolution will likely increase. The timeline for any of the more ambitious applications is genuinely unknown — and anyone who gives you a confident prediction about when brain-computer interfaces will be a consumer product is working from speculation, not data.
What I do know is that as this technology develops, the people building it need to be talking seriously to security researchers, ethicists, and lawyers — not just neuroscientists and engineers. The questions that matter most about this technology are not purely technical.
Sources referenced:
- FDA PRIME Study approval documentation — Neuralink BCI trial
- Neuralink company disclosures regarding electrode retraction (2024)
- Synchron FDA Breakthrough Device Designation documentation
- Blackrock Neurotech published clinical literature
- Published BCI vulnerability research (academic literature)
This article is for informational and educational purposes only. It does not constitute medical or investment advice.
